One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients*


      This phase I open label, dose-escalating study shows that gene transfer of vascular endothelial growth factor-2 naked deoxyribonucleic acid by direct myocardial injection by way of thoracotomy in patients with Canadian Cardiovascular Society class 3 or 4 angina is feasible and safe. The procedure is well tolerated, with few major adverse cardiac events at 1 year, and without complications directly related to gene expression. In this prospective, nonblinded study, the procedure is associated with clinical improvement; however, there was no angiographic evidence of angiogenesis and there is a great potential for a sham or placebo effect in the study patients. A randomized phase III trial is underway that will help determine the efficacy of vascular endothelial growth factor-2 gene transfer in “no-option” patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Losordo D.W.
        • Vale P.R.
        • Symes J.F.
        • Dunnington C.H.
        • Esakof D.D.
        • Maysky M.
        • Ashare A.B.
        • Lathi K.
        • Isner J.M.
        Gene therapy for myocardial angiogenesis.
        Circulation. 1998; 98: 2800-2804
        • Symes J.F.
        • Losordo D.W.
        • Vale P.R.
        • Lathi K.G.
        • Esakof D.D.
        • Mayskiy M.
        • Isner J.M.
        Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
        Ann Thorac Surg. 1999; 68: 830-836
        • Witzenbichler B.
        • Asahara T.
        • Murohara T.
        • Silver M.
        • Spyridopoulos I.
        • Magner M.
        • Principe N.
        • Kearney M.
        • Hu J.S.
        • Isner J.M.
        Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia.
        Am J Pathol. 1998; 153: 381-394
        • Joukov V.
        • Pajusola K.
        • Kaipainen A.
        • Chilov D.
        • Lahtinen I.
        • Kukk E.
        • Saksela O.
        • Kalkkinen N.
        • Alitalo K.
        A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
        EMBO J. 1996; 15: 290-298
        • Jeltsch M.
        • Kaipainen A.
        • Joukov V.
        • Meng X.
        • Lakso M.
        • Rauvala H.
        • Swartz M.
        • Fukumura D.
        • Jain R.K.
        • Alitalo K.
        Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
        Science. 1997; 276: 1423-1425
        • Zar J.H.
        Biostatistical Analysis.
        Prentice-Hall, Englewood Cliffs, NJ1984
        • Henry T.D.
        • Rocha-Singh K.
        • Isner J.M.
        • Kereiakes D.J.
        • Giordano F.J.
        • Simons M.
        • Losordo D.W.
        • Hendel R.C.
        • Bonow R.O.
        • Eppler S.M.
        • et al.
        Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.
        Am Heart J. 2001; 142: 872-880
        • Vale P.R.
        • Losordo D.W.
        • Milliken C.E.
        • Maysky M.
        • Esakof D.D.
        • Symes J.F.
        • Isner J.M.
        Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.
        Circulation. 2000; 102: 965-974
        • Burkhoff D.
        • Schmidt S.
        • Schulman S.P.
        • Myers J.
        • Resar J.
        • Becker L.C.
        • Weiss J.
        • Jones J.W.
        Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris.
        Lancet. 1999; 354: 885-890
        • Frazier O.H.
        • March R.J.
        • Horvath K.A.
        Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease.
        New Engl J Med. 1999; 341: 1021-1028
        • Schofield P.M.
        • Sharples L.D.
        • Caine N.
        • Burns S.
        • Tait S.
        • Wistow T.
        • Buxton M.
        • Wallwork J.
        Transmyocardial laser revascularisation in patients with refractory angina.
        Lancet. 1999; 353: 519-524
        • Aaberge L.
        • Nordstrand K.
        • Dragsund M.
        • Saatvedt K.
        • Endresen K.
        • Golf S.
        • Geiran O.
        • Abdelnoor M.
        • Forfang K.
        Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial.
        J Am Coll Cardiol. 2000; 35: 1170-1177
        • Allen K.B.
        • Dowling R.D.
        • Fudge T.L.
        • Schoettle G.P.
        • Selinger S.L.
        • Gangahar D.M.
        • Angell W.W.
        • Petracek M.R.
        • Shaar C.J.
        • O'Neill W.W.
        Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina.
        New Engl J Med. 1999; 341: 1029-1036
        • Grines C.L.
        • Watkins M.W.
        • Helmer G.
        • Penny W.
        • Brinker J.
        • Marmur J.D.
        • West A.
        • Rade J.J.
        • Marrott P.
        • Hammond H.K.
        • Engler R.L.
        Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris.
        Circulation. 2002; 105: 1291-1297